Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Research Article

Ameliorating Effects of Virgin Coconut Oil (VCO) on Nicotine Dependence and Quality of Life in Smokers

Author(s): Kusnandar Anggadiredja*, Lia Amalia and Fahmy Ahsanul Haq

Volume 22, Issue 8, 2023

Published on: 13 January, 2023

Page: [1243 - 1249] Pages: 7

DOI: 10.2174/1871527322666221128141647

open access plus

Abstract

Background: Safer and effective alternatives to manage nicotine dependence are still required. Preliminary studies have shown the potential of virgin coconut oil (VCO) to be used in dependence treatment.

Objective: To assess the VCO effect administered for 14 days on nicotine dependence and quality of life.

Methods: Forty smoking subjects participated in an open-label, single-center, pre/post-intervention study, and were required to take 15 ml VCO twice daily for 14 days. They were evaluated with the Fagerstrom Test for Nicotine Dependence (FTND) for nicotine dependence intensity and EuroQolvisual analogue scales (EQ VAS) for quality of life.

Results: The VCO regimen improved FTND (0.53 points decrease, p<0.05) and EQ-VAS (5.85 points increase p<0.01) scores. Adverse events were all mild.

Conclusion: Results of the present study suggest that VCO has the potential to be a safe and effective adjunct therapy for the management of nicotine dependence.

Graphical Abstract

[1]
World Health Organization. WHO Report on the Global Tobacco Epidemic. Available from: https://www.who.int/teams/healthpromotion/tobaccocontrol/who-report-on-the-global-tobaccoepidemic-2019 [Accessed June 17, 2021].
[2]
Bruijnzeel AW. Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology 2017; 234(9-10): 1419-37.
[http://dx.doi.org/10.1007/s00213-016-4513-5] [PMID: 28028605]
[3]
Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010; 70(18): 2357-72.
[http://dx.doi.org/10.2165/11538190-000000000-00000] [PMID: 21142259]
[4]
Solinas M, Belujon P, Fernagut PO, Jaber M, Thiriet N. Dopamine and addiction: what have we learned from 40 years of research. J Neural Transm 2019; 126(4): 481-516.
[http://dx.doi.org/10.1007/s00702-018-1957-2] [PMID: 30569209]
[5]
Anggadiredja K, Yamaguchi T, Tanaka H, Shoyama Y, Watanabe S, Yamamoto T. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice. Brain Res 2003; 966(1): 47-53.
[http://dx.doi.org/10.1016/S0006-8993(02)04169-0] [PMID: 12646307]
[6]
Anggadiredja K, Nakamichi M, Hiranita T, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 2004; 29(8): 1470-8.
[http://dx.doi.org/10.1038/sj.npp.1300454] [PMID: 15085091]
[7]
Intahphuak S, Khonsung P, Panthong A. Anti-inflammatory, analgesic, and antipyretic activities of virgin coconut oil. Pharm Biol 2010; 48(2): 151-7.
[http://dx.doi.org/10.3109/13880200903062614] [PMID: 20645831]
[8]
Anggadired K, Barlian A, Marga Pina YD, Anggraeny D. Virgin coconut oil prevents nicotine dependence and relapse. Int J Pharmacol 2011; 7(5): 664-9.
[http://dx.doi.org/10.3923/ijp.2011.664.669]
[9]
Liau KM, Lee YY, Chen CK, Rasool AHG. An open-label pilot study to assess the efficacy and safety of virgin coconut oil in reducing visceral adiposity. ISRN Pharmacol 2011; 2011: 1-7.
[http://dx.doi.org/10.5402/2011/949686] [PMID: 22164340]
[10]
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Addiction 1991; 86(9): 1119-27.
[http://dx.doi.org/10.1111/j.1360-0443.1991.tb01879.x] [PMID: 1932883]
[11]
Anggadiredja K, Yamaguchi T, Tanaka H, Shoyama Y, Watanabe S, Yamamoto T. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: A quasi abstinence approach. Brain Res 2005; 1066(1-2): 201-5.
[http://dx.doi.org/10.1016/j.brainres.2005.10.065] [PMID: 16336946]
[12]
Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006; 17(5-6): 431-9.
[http://dx.doi.org/10.1097/00008877-200609000-00009] [PMID: 16940764]
[13]
Miller NS, Klamen D, Hoffmann NG, Flaherty JA. Prevalence of depression and alcohol and other drug dependence in addictions treatment populations. J Psychoactive Drugs 1996; 28(2): 111-24.
[http://dx.doi.org/10.1080/02791072.1996.10524384] [PMID: 8811580]
[14]
Yeap SK, Beh BK, Ali NM, et al. Antistress and antioxidant effects of virgin coconut oil in vivo. Exp Ther Med 2015; 9(1): 39-42.
[http://dx.doi.org/10.3892/etm.2014.2045] [PMID: 25452773]
[15]
Hughes JR, Keely J, Naud S. Shape of the relapse curve and longterm abstinence among untreated smokers. Addiction 2004; 99(1): 29-38.
[http://dx.doi.org/10.1111/j.1360-0443.2004.00540.x] [PMID: 14678060]
[16]
Jarvis MJ. Why people smoke. BMJ 2004; 328(7434): 277-9.
[http://dx.doi.org/10.1136/bmj.328.7434.277] [PMID: 14751901]
[17]
Vysakh A, Ratheesh M, Rajmohanan TP, et al. Polyphenolics isolated from virgin coconut oil inhibits adjuvant induced arthritis in rats through antioxidant and anti-inflammatory action. Int Immunopharmacol 2014; 20(1): 124-30.
[http://dx.doi.org/10.1016/j.intimp.2014.02.026] [PMID: 24613207]
[18]
Lichtman AH, Fisher J, Martin BR. Precipitated cannabinoid withdrawal is reversed by Δ9-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 2001; 69(1-2): 181-8.
[http://dx.doi.org/10.1016/S0091-3057(01)00514-7] [PMID: 11420084]
[19]
Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 1997; 21(1): 91-104.
[http://dx.doi.org/10.1016/0149-7634(95)00061-5] [PMID: 8994212]
[20]
Silverstone PH, Done C, Sharp T. Clonidine but not nifedipine prevents the release of noradrenaline during naloxone-precipitated opiate withdrawal: an in vivo microdialysis study in the rat. Psychopharmacology 1992; 109(1-2): 235-8.
[http://dx.doi.org/10.1007/BF02245506] [PMID: 1365663]
[21]
Vargas ML, Martínez-Piñero MG, Milanés MV. Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: the role of calcium channels. Naunyn Schmiedebergs Arch Pharmacol 1997; 355(4): 501-6.
[http://dx.doi.org/10.1007/PL00004975] [PMID: 9109367]
[22]
Exner H, Schlicker E. Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1995; 351(1): 46-52.
[http://dx.doi.org/10.1007/BF00169063] [PMID: 7715741]
[23]
Hillier K, Templeton WW. Regulation of noradrenaline overflow in rat cerebral cortex by prostaglandin E2. Br J Pharmacol 1980; 70(3): 469-73.
[http://dx.doi.org/10.1111/j.1476-5381.1980.tb08725.x] [PMID: 6108146]
[24]
Ibrahim AH, Khan MSS, Al-Rawi SS, et al. Safety assessment of widely used fermented virgin coconut oil (Cocos nucifera) in Malaysia: Chronic toxicity studies and SAR analysis of the active components. Regul Toxicol Pharmacol 2016; 81: 457-67.
[http://dx.doi.org/10.1016/j.yrtph.2016.10.004] [PMID: 27756558]
[25]
Chinwong S, Chinwong D, Mangklabruks A. Daily Consumption of virgin coconut oil increases high-density lipoprotein cholesterol levels in healthy volunteers: a randomized crossover trial. Evid Based Complement Alternat Med 2017; 2017: 1-8.
[http://dx.doi.org/10.1155/2017/7251562] [PMID: 29387131]

© 2024 Bentham Science Publishers | Privacy Policy